TY - JOUR
T1 - Encapsulation of asparaginase as a promising strategy to improve in vivo drug performance
AU - Villanueva-Flores, Francisca
AU - Zárate-Romero, Andrés
AU - Torres, Alfredo G.
AU - Huerta-Saquero, Alejandro
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the development of improved formulations (biobetters), but only two of them are currently on the market. Nano-and micro-encapsulation are some of the most promising and novel approaches to enhance in vivo performance of ASNase, preventing the direct contact of the enzyme with the environment, protecting it from protease degradation, increasing the enzymes catalytic half-life, and in some cases, reducing immunogenicity. This review summarizes the strategies, particularly for ASNase nano-and micro-encapsulation, and their main findings, constraints, and current gaps in the state-of-the-art knowledge. The pros and cons of the use of different nanocarriers are discussed with the idea to ultimately provide safer and more effective treatments for patients with ALL.
AB - Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the development of improved formulations (biobetters), but only two of them are currently on the market. Nano-and micro-encapsulation are some of the most promising and novel approaches to enhance in vivo performance of ASNase, preventing the direct contact of the enzyme with the environment, protecting it from protease degradation, increasing the enzymes catalytic half-life, and in some cases, reducing immunogenicity. This review summarizes the strategies, particularly for ASNase nano-and micro-encapsulation, and their main findings, constraints, and current gaps in the state-of-the-art knowledge. The pros and cons of the use of different nanocarriers are discussed with the idea to ultimately provide safer and more effective treatments for patients with ALL.
KW - Acute lymphoblastic leukemia
KW - Asparaginase
KW - Biobetter
KW - Nanocarrier
KW - Quality by design
UR - http://www.scopus.com/inward/record.url?scp=85120347781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120347781&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics13111965
DO - 10.3390/pharmaceutics13111965
M3 - Review article
C2 - 34834379
AN - SCOPUS:85120347781
SN - 1999-4923
VL - 13
JO - Pharmaceutics
JF - Pharmaceutics
IS - 11
M1 - 1965
ER -